ADIA Nutrition Realigns Market Classification to Accurately Reflect Biotech Operations

Reclassification from pharma holding company status to biological products manufacturer marks strategic clarity for regenerative medicine pioneer

ADIA Nutrition Inc. (OTCQB: ADIA) has formally requested regulatory reclassification with both the SEC and OTC Markets Group, shifting its Standard Industrial Classification (SIC code 2836) designation to align with its actual business operations in biological products manufacturing and distribution. Previously categorized as pharmaceutical preparations (SIC 2834) with SEC and as a holding company (SIC 6719) with OTC Markets, the company’s true operational footprint had become obscured by outdated classifications.

The Winter Park, Florida-based company operates through a dual-channel model that distinguishes it from traditional pharma or supplement businesses. Adia Labs LLC manufactures and distributes FDA-registered 361 HCT/Ps—namely AdiaVita and AdiaLink—to physicians across the nation, while Adia Med operates a network of specialty clinics delivering stem cell therapies, platelet-rich plasma (PRP) treatments, therapeutic plasma exchange (TPE), autologous hematopoietic stem cell transplantation (aHSCT), and wound repair services.

Why SIC Code 2836 Matters

The shift to biological products classification addresses a fundamental mismatch between how regulators and investors have categorized ADIA versus how it actually operates. “We are not a supplement, pharma, or holding company,” CEO Larry Powalisz stated. “We are a biotech company scaling biological products through labs and clinics. Updating to SIC 2836 across both SEC and OTC Markets gives investors and partners full clarity on our true growth model.”

This precision in classification has real implications. Biotech companies pursuing partnerships, financing, or strategic alliances benefit from transparent operational categorization. ADIA’s reclassification removes ambiguity about what sector benchmarks apply to the business and clarifies its positioning within the regenerative medicine landscape.

Business Traction Validates Reclassification

The timing of the SIC code update coincides with ADIA’s operational momentum. The company posted 200%+ quarter-over-quarter revenue growth in Q3 2025, expanded its clinic network nationwide, and progressed toward OTCQB uplisting—metrics that substantiate its biotech growth narrative rather than a holding company or pharmaceutical preparation model.

The company generates revenue through multiple streams: direct service fees from Adia Med clinics, product sales through Adia Labs, insurance billing for FDA-approved treatments, and strategic equity positions in complementary health ventures like Cement Factory LLC, a nutrition and supplement company aligned with Adia’s wellness mission.

Implementation and Next Steps

Upon ADIA’s next regulatory filings, the updated SIC code classifications will take effect across both the SEC and OTC Markets databases. This change streamlines how institutional investors, research analysts, and potential partners identify and evaluate the company’s business model.

For business development opportunities, clinic owners and healthcare practitioners interested in licensing the Adia Med brand or integrating regenerative therapies into their practices are encouraged to engage directly with the company. Additional inquiries can be directed to CEO Larry Powalisz at 321-788-0850 or ceo@adiamed.com.

About ADIA Nutrition Inc.

ADIA Nutrition Inc. (OTCQB: ADIA) is a publicly traded regenerative medicine company headquartered in Winter Park, Florida. The company combines FDA-registered biological product manufacturing with clinical delivery of advanced regenerative treatments, positioning itself at the intersection of biotech innovation and healthcare delivery.